NewGenIvf Group Limited (NIVF) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Medical - Healthcare Plans
EV/EBITDA
N/A
—
5yr avg: 126106.75
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.01
↓-100% vs avg
5yr avg: 109770.04
30Y Low0.2·High0.2
ROE
↓
80.6%
↑-33% vs avg
5yr avg: 121.1%
30Y Low-60%·High456%
Debt/EBITDA
↓
N/A
—
5yr avg: 1.47
30Y Low1.2·High1.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NIVF Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NewGenIvf Group Limited trades at 0.0x earnings, 100% below its 5-year average of 4158.9x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.5x, the stock trades at a discount of 100%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $355791 | $5M | $2.9B | $34.3B | $32.1B | — |
| Enterprise Value | $4M | $9M | $2.9B | $34.3B | $32.1B | — |
| P/E Ratio → | 0.04 | 0.49 | — | 10518.36 | 1957.91 | — |
| P/S Ratio | 0.08 | 1.03 | 526.20 | 6677.07 | 5399.07 | — |
| P/B Ratio | 0.01 | 0.19 | — | 10566.57 | 318743.36 | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NIVF EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.90 | 526.67 | 6677.12 | 5399.14 | — |
| EV / EBITDA | — | — | — | 126106.75 | — | — |
| EV / EBIT | — | 0.87 | — | 221833.09 | 76094.51 | — |
| EV / FCF | — | — | — | — | — | — |
NIVF Profitability
Margins and return-on-capital ratios measuring operating efficiency
NewGenIvf Group Limited earns an operating margin of -226.9%. Operating margins have compressed from 0.8% to -226.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 80.6% is exceptionally high.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 20.2% | 20.2% | 33.6% | 32.7% | 25.9% | 24.9% |
| Operating Margin | -226.9% | -226.9% | -21.4% | 0.8% | -8.5% | 4.8% |
| Net Profit Margin | 209.0% | 209.0% | -9.7% | 2.5% | 7.7% | -0.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | 80.6% | 80.6% | -59.5% | 7.8% | 455.6% | — |
| ROA | 54.4% | 54.4% | -13.0% | 3.5% | 21.2% | -0.0% |
| ROIC | -51.6% | -51.6% | -37.7% | 1.6% | -149.2% | — |
| ROCE | -68.7% | -68.7% | -55.0% | 2.3% | -144.5% | — |
NIVF Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $4M ($5M total debt minus $758621 cash). Interest coverage of 16.8x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.19 | — | 0.10 | 4.49 | — |
| Debt / EBITDA | — | — | — | 1.22 | — | 1.71 |
| Net Debt / Equity | — | 0.16 | — | 0.09 | 4.22 | — |
| Net Debt / EBITDA | — | — | — | 1.02 | — | 1.66 |
| Debt / FCF | — | — | — | — | — | 0.63 |
| Interest Coverage | 16.78 | 16.78 | -0.23 | 3.35 | 5.42 | 2.77 |
NIVF Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
NewGenIvf Group Limited's current ratio of 3.12x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.19x to 3.12x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 3.12 | 3.12 | 1.17 | 2.19 | 0.94 | 0.40 |
| Quick Ratio | 2.98 | 2.98 | 1.14 | 2.08 | 0.92 | 0.38 |
| Cash Ratio | 0.32 | 0.32 | 0.17 | 0.05 | 0.01 | 0.01 |
| Asset Turnover | — | 0.14 | 1.52 | 1.14 | 2.05 | 2.91 |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
NIVF Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NewGenIvf Group Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 100.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 202.9% | — | 0.0% | 0.1% | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $588235 | $588235 | $262190 | $262190 | $262190 |
Peer Comparison
Compare NIVF with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NIVFYou | $355791 | 0.0 | — | — | 20.2% | -226.9% | 80.6% | -51.6% | — |
 NTRA | $37B | -171.0 | — | 341.2 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 PGNY | $2B | 41.4 | 22.4 | 11.0 | 23.6% | 6.6% | 12.5% | 18.1% | 0.3 |
 TMHC | $7B | 9.3 | 7.2 | 8.3 | 23.0% | 14.0% | 12.8% | 11.0% | 2.1 |
 HIMS | $7B | 64.1 | 51.3 | 97.1 | 73.8% | 4.5% | 25.2% | 8.6% | 7.9 |
 ILMN | $27B | 32.1 | 24.5 | 28.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 IART | $1B | -2.6 | 14.5 | — | 51.7% | 4.2% | -39.9% | 1.7% | 9.3 |
 QDEL | $831M | -0.7 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 FGEN | $585M | -15.6 | — | — | 47.5% | -507.8% | — | — | — |
 CLOV | $3B | -30.6 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
| Healthcare Median | — | 22.5 | 14.3 | 19.1 | 63.6% | -4.8% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
NIVF — Frequently Asked Questions
Quick answers to the most common questions about buying NIVF stock.
What is NewGenIvf Group Limited's P/E ratio?
NewGenIvf Group Limited's current P/E ratio is 0.0x. The historical average is 0.5x.
What is NewGenIvf Group Limited's ROE?
NewGenIvf Group Limited's return on equity (ROE) is 80.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 121.1%.
Is NIVF stock overvalued?
Based on historical data, NewGenIvf Group Limited is trading at a P/E of 0.0x. Compare with industry peers and growth rates for a complete picture.
What are NewGenIvf Group Limited's profit margins?
NewGenIvf Group Limited has 20.2% gross margin and -226.9% operating margin.